Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Net Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of Net Margin readings, the most recent being 70.93% for Q4 2025.

  • On a quarterly basis, Net Margin fell 8771.0% to 70.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.02%, a 3002.0% decrease, with the full-year FY2025 number at 33.02%, down 3002.0% from a year prior.
  • Net Margin hit 70.93% in Q4 2025 for Cytek Biosciences, down from 10.48% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 16.78% in Q4 2024 to a low of 70.93% in Q4 2025.
  • Median Net Margin over the past 5 years was 7.3% (2022), compared with a mean of 9.13%.
  • Biggest five-year swings in Net Margin: soared 1528bps in 2024 and later crashed -8771bps in 2025.
  • Cytek Biosciences' Net Margin stood at 1.01% in 2021, then surged by 625bps to 7.3% in 2022, then rose by 29bps to 9.45% in 2023, then skyrocketed by 78bps to 16.78% in 2024, then tumbled by -523bps to 70.93% in 2025.
  • The last three reported values for Net Margin were 70.93% (Q4 2025), 10.48% (Q3 2025), and 12.24% (Q2 2025) per Business Quant data.